Influence of donor C3 allotype on late renal-transplantation outcome

New England Journal of Medicine

Volumn 354, Issue 19, 2006, Pages 2014-2023

  Brown, Katherine M ^a   Kondeatis, Elli ^a   Vaughan, Robert W ^a   Kon, Sui P ^b   Farmer, Christopher K T ^c   Taylor, John D ^a   He, Xiang ^d   Johnston, Atholl ^d   Horsfield, Catherine ^e   Janssen, Bert J C ^f   Gros, Piet ^f   Zhou, Wuding ^a   Sacks, Steven H ^a   Sheerin, Neil S ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CYCLOSPORIN; PREDNISONE;

ALLELE; ALLOTYPE; ARTICLE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN POLYMORPHISM;

EID: 33646486869     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa052825     Document Type: Article

References (35)

1. 2004 Annual report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1994-2003. Rockville, Md.: Health Resources and Services Administration, Division of Transplantation, 2004.
2. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999;56:783-93.
3. Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol 2003;15:487-92.
4. Walport MJ. Complement: first of two parts. N Engl J Med 2001;344:1058-66.
5. Erdei A, Fust G, Gergely J. The role of C3 in the immune response. Immunol Today 1991;12:332-7.
6. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH. Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 1999;162:4336-41.
7. Naughton MA, Botto M, Carter MJ, Alexander GJ, Goldman JM, Walport MJ. Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol 1996;156:3051-6.
8. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002;8:582-7.
9. Alper CA, Propp RP. Genetic polymorphism of the third component of human complement (C3). J Clin Invest 1968;47:2181-91.
10. Botto M, Fong KY, So AK, Koch C, Walport MJ. Molecular basis of polymorphisms of human complement component C3. J Exp Med 1990;172:1011-7.
11. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
12. Poznansky MC, Clissold PM, Lachmann PJ. The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3. J Immunol 1989;143:1254-8.
13. Rambausek M, van den Wall Bake AW, Schumacher-Ach R, et al. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol Dial Transplant 1987;2:208-11.
14. Finn JE, Zhang L, Agrawal S, Jayne DR, Oliveira DB, Mathieson PW. Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant 1994;9:1564-7.
15. McLean RH, Winkelstein JA. Genetically determined variation in the complement system: relationship to disease. J Pediatr 1984;105:179-88.
16. Finn JE, Mathieson PW. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immunol 1993;91:410-4.
17. Andrews PA, Finn JE, Mathieson PW, Sacks SH. Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts. Transplantation 1995;60:1342-6.
18. Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005;79:304-9.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-23.
20. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002;13:2140-4.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
22. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000;105:1363-71.
23. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993;43:1333-8.
24. Sacks SH, Chowdhury P. Footprints of humoral rejection. Curr Opin Nephrol Hypertens 2002;11:627-8.
25. Heeger PS, Lalli PN, Lin F, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005;201:1523-30.
26. Pratt JR, Abe K, Miyazaki M, Zhou W, Sacks SH. In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol 2000;157:825-31.
27. Li K, Patel H, Farrar CA, Hargreaves RE, Sacks SH, Zhou W. Complement activation regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. J Am Soc Nephrol 2004;15:2414-22.
28. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH. Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 2006;107:2461-9.
29. Arvilommi H. Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature 1974;251:740-1.
30. Bartok I, Walport MJ. Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3. J Immunol 1995;154:5367-75.
31. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003;421:388-92.
32. Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005;437:505-11.
33. Koch C, Behrendt N. A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody. Immunogenetics 1986;23:322-5.
34. Exner M, Bohmig GA, Schillinger M, et al. Donor heme oxygenase-1 genotype is associated with renal allograft function. Transplantation 2004;77:538-42.
35. Hoffmann S, Park J, Jacobson LM, et al. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 2004;66:1686-93.